Interaction of lp-dlg/KIAA0583, a Membrane-associated Guanylate Kinase Family Protein, with Vinexin and {beta}-Catenin at Sites of Cell-Cell Contact*

Makoto Wakabayashi, Takuya Ito, Masaru Mitsushima, Sanae Aizawa, Kazumitsu Ueda, Teruo Amachi and Noriyuki Kioka {ddagger}

From the Division of Applied Life Sciences, Graduate School of Agriculture, Kyoto University, Sakyo-ku, Kyoto 606-8502, Japan

Received for publication, October 28, 2002 , and in revised form, March 17, 2003.
    ABSTRACT
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Vinexin is a recently identified cytoskeletal protein and plays a key role in the regulation of cytoskeletal organization and signal transduction. Vinexin localizes at sites of cell-extracellular matrix adhesion in NIH3T3 fibroblasts and at sites of cell-cell contact in epithelial LLC-PK1 cells. Expression of vinexin promotes the formation of actin stress fiber, but the role of vinexin at sites of cell-cell contact is unclear. Here we identified lp-dlg/KIAA0583 as a novel binding partner for vinexin by using yeast two-hybrid screening. lp-dlg/KIAA0583 has a NH2-terminal coiled-coil-like domain, in addition to four PDZ domains, an Src homology (SH) 3 domain, and a guanylate kinase domain, which are conserved structures in membrane-associated guanylate kinase family proteins. The third SH3 domain of vinexin bound to the region between the second and third PDZ domain of lp-dlg, which contains a proline-rich sequence. lp-dlg colocalized with vinexin at sites of cell-cell contact in LLC-PK1 cells. Furthermore, lp-dlg colocalized with {beta}-catenin, a major adherens junction protein, in LLC-PK1 cells. Co-immunoprecipitation experiments revealed that both endogenous and epitope-tagged deletion mutants of lp-dlg/KIAA0583 associated with {beta}-catenin. We also showed that these three proteins could form a ternary complex. Together these findings suggest that lp-dlg/KIAA0583 is a novel scaffolding protein that can link the vinexin-vinculin complex and {beta}-catenin at sites of cell-cell contact.


    INTRODUCTION
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Cell-cell adhesion is important for cell polarity, tissue morphogenesis development, and homeostasis (13). To this end, epithelial cells exhibit specialized structures involved in cell-cell contacts such as tight junctions and adherens junctions. Adherens junctions contain the transmembrane cell adhesion molecules, cadherins and nectins, which mediate the calcium-dependent and -independent cell-cell adhesion (1, 3, 4), respectively. The cytoplasmic domain of cadherin binds to {beta}-catenin, which then binds to {alpha}-catenin. {alpha}-Catenin binds to actin and actin-binding proteins such as vinculin, {alpha}-actinin, and ZO-1, resulting in the link of cadherin to the actin cytoskeleton (3, 5, 6). The cytoplasmic domain of nectin binds to l-afadin, which then binds to actin and a vinculin-binding protein ponsin (4, 7, 8). Multiple protein complexes of these cytoplasmic proteins play important roles in communicating between cell adhesion systems, regulating cell-cell adhesion, and transducing signals into cells.

Vinexin is a protein localizing at cell-cell and cell-extracellular matrix junctions (9). There are at least two types of vinexin, vinexin {alpha} and vinexin {beta}, which share a common carboxyl-terminal sequence containing three SH (Src homology) 31 domains. The larger vinexin {alpha} has an additional amino-terminal sequence containing a sorbin homology domain. Vinexin is a member of a novel adaptor protein family, including ArgBP2 and ponsin, all of which have a sorbin homology domain in the NH2-terminal half and three SH3 domains in the COOH-terminal half (812). Vinexin binds to vinculin, which also localizes at cell-cell and cell-matrix junctions, through its first and second SH3 domains and enhances actin stress fiber formation and cell spreading (9). Furthermore, vinexin {beta} regulates the anchorage dependence of extracellular signal-regulated kinase activation induced by epidermal growth factor (13, 14). Therefore, vinexin plays a crucial role in regulating cell-extracellular matrix communication, but little is known about the function of vinexin at cell-cell junctions.

Vinculin is a part of the cadherin-catenin junctional complex and is involved in apical junctional organization (1518), suggesting that its binding partner vinexin may have important roles at sites of cell-cell contact. In this study, we identified a membrane-associated guanylate kinase (MAGUK) family protein lp-dlg/KIAA0583 as a vinexin-binding protein. lp-dlg colocalized with vinexin and {beta}-catenin at sites of cell-cell contact. lp-dlg was also co-immunoprecipitated with {beta}-catenin. These findings suggest that lp-dlg/KIAA0583 is a scaffolding protein that can link the vinexin-vinculin complex and {beta}-catenin at sites of cell-cell contact.


    EXPERIMENTAL PROCEDURES
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Yeast Two-hybrid Screening—The plasmid pGBT9-vinexin {beta} was constructed by subcloning the full-length vinexin {beta} into the EcoRI/SalI site of pGBT9 (Clontech). Yeast two-hybrid screening was performed as described previously (9). Briefly, the yeast strain HF7c was transformed first with pGBT9-vinexin {beta} and subsequently with a human placenta cDNA library (Clontech) fused to the GAL4 transcriptional activating domain. Transformants were screened for tryptophan, leucine, and histidine autotorophy. Histidine-positive colonies were further tested for {beta}-galactosidase activity. Prey plasmids from dual positive colonies were confirmed for the specific interaction by using various bait plasmids.

To define the lp-dlg binding site of vinexin {beta}, a deletion mutant containing only the third SH3 domain was excised from plasmids of GST-3rdSH3 (14) and subcloned into pGBT9. Deletion mutants containing the second and third SH3 (amino acids 120–328) and the linker (amino acids 173–271) region of mouse vinexin {beta} were amplified by polymerase chain reaction and subcloned into pGBT9. pGBT9–1stSH3, 2ndSH3, and 1st+2ndSH3 were described previously (9). After cotransformation of vinexin deletion mutants in pGBT9 with pMW6 into HF7c, transformants were plated on -Trp, -Leu, -His agar selection media.

PCR-based Full-length lp-dlg cDNA Cloning—A 5'-rapid amplification of cDNA ends experiment was performed using Human Placenta Marathon Ready (Clontech) cDNA as described previously (19). Primer sets 5'-GACTGATGCCACTGTCTTTCTGTCCAC and AP1 and 5'-CCAGTCATTGACCCTTAAGCGGC and AP2 were used for the first PCR and second PCR, respectively. The several PCR fragments generated by independent PCR were ligated into pCR2.1 (Invitrogen) and sequenced to exclude the fragments containing nucleotide errors introduced by the PCR reaction artificially. The cDNA fragment from one of the longest clones was combined with KIAA0583 cDNA (provided by Dr. Takahiro Nagase) using AflII to construct the full-length lp-dlg cDNA. The resulting full-length cDNA was subcloned into pGZ21 (9) for expressing as GFP-tagged protein.

Antibodies—The cDNA insert of the clone (pMW6) isolated by the yeast two-hybrid screening was subcloned into pGEX4T-1 (Amersham Biosciences) for expressing as GST-tagged protein and designed pGST-MW6. Rabbit anti-lp-dlg antiserum was raised against GST-MW6. Polyclonal antibodies were affinity purified using GST-MW6 covalently conjugated to Affi-Gel 10 (Bio-Rad) followed by the adsorption with Affi-Gel 10 conjugated with GST. Anti-FLAG antibody M2, anti-GFP antibody, and anti-{beta}-catenin antibody were obtained from Sigma, Santa Cruz Biotechnology, and Transduction Laboratories, respectively. Anti-HA antibodies were purchased from Roche Diagnostics and Santa Cruz Biotechnology.

Northern Blotting—A cDNA fragment of 1–1557 base pairs of the lp-dlg coding region was radiolabeled using a Random Primer DNA labeling kit version 2.0 (TAKARA) and then used to probe the Human Multiple Northern blot (Clontech) containing 2 µg of poly(A)+ RNA, as described previously (9).

In Vitro Binding Assay Using Affinity Precipitation—The GST-fused proteins containing vinexin deletion mutants, GST-1stSH3, GST-2ndSH3, GST-3rdSH3, GST-3rdSH3WF, and GST-3rdSH3YV were described previously (14). Full-length vinexin {beta} was subcloned into pGEX4T-1. The cDNA insert of pMW6 was subcloned into p401F (9) to make FLAG-tagged MW6. To construct FLAG-tagged lp-dlg deletion mutants (644–909, 842–909, 842–879, and 880–909), the corresponding region of lp-dlg was amplified by PCR and subcloned into p401F. In vitro binding assays were performed as described previously (12). In brief, COS-7 cells were transiently transfected with various FLAG-tagged constructs and washed twice with phosphate-buffered saline and lysed in Triton lysis buffer (1% Triton X-100, 100 µg/ml p-amidinophenylmethanesulfonyl fluoride hydrochloride, 10 µg/ml aprotinin, 10 µg/ml leupeptin). The lysates were incubated with 3 µg of each GST fusion protein and glutathione-Sepharose 4B (Amersham Biosciences) at 4 °C for 3 h. After four washes with lysis buffer, co-precipitated proteins were resolved by 8% SDS-PAGE and analyzed by Western blot with anti-FLAG M2 antibody.

Immunoprecipitation—COS-7 cells were transiently transfected with p401F-MW6 with or without expression plasmid for GFP-tagged vinexin {beta} (9). COS-7 cells were lysed as described above and equal amounts of total proteins were incubated with 5 µg of anti-FLAG antibody M2 for 1 h at 4 °C. The immunocomplexes were incubated with protein G-Sepharose for 1 h and washed four times with lysis buffer. The bound proteins were detected as described above with anti-GFP antibody. To examine the interaction of FLAG-vinexins with endogenous lp-dlg, FLAG-tagged vinexin genes were subcloned into the pLRT-X, which was designed for the tetracycline-On (Tet-ON) expression system (20). Then the plasmids were stably transfected into LLC-PK1 cells. After inducing the expression of FLAG-tagged vinexin {alpha} and {beta} by adding the tetracycline derivative doxycycline (1.5 µg/ml), immunoprecipitation was performed as described above, followed by immunoblotting using anti-lp-dlg antibody.

To detect the interaction of lp-dlg and {beta}-catenin, FLAG-tagged lp-dlg mutants were transfected into COS-7 cells with GFP-tagged {beta}-catenin. Cells were then lysed and immunoprecipitated with anti-FLAG M2 antibody as described above. The bound proteins were detected using anti-GFP antibody. To detect the interaction of endogenous lp-dlg with {beta}-catenin, endogenous lp-dlg from LLC-PK1 cells was immunoprecipitated with anti-lp-dlg antibody. Co-precipitated {beta}-catenin was detected as described above using anti-{beta}-catenin antibody.

Immunostaining—For immunostaining of endogenous lp-dlg with GFP-vinexin {beta}, LLC-PK1 cells were transfected with GFP-tagged vinexin {beta} using LipofectAMINE (Invitorgen). The cells were fixed with methanol at room temperature for 1 min. For co-immunostaining of endogenous lp-dlg and {beta}-catenin, LLC-PK1 cells were fixed with acetone at room temperature for 30 s. Immunofluorescence staining was carried out as described previously (9). The fluorescence images were obtained using an Axiovert microscope (Carl Zeiss) equipped with a MicroRadiance confocal laser scanning microscope (Bio-Rad).


    RESULTS
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Identification of lp-dlg/KIAA0583 as a Novel Vinexin Binding Partner—Vinexin binds to vinculin and localizes at cell-cell and cell-matrix junctions, but little is known about the function of vinexin at cell-cell junctions. To elucidate the function of vinexin at sites of cell-cell contact, we first performed the yeast two-hybrid screening using mouse vinexin {beta} as a bait to isolate vinexin-binding proteins localizing at sites of cell-cell contact. The cDNA library constructed from human placenta poly(A)+ RNA was screened, and four independent clones were isolated as positive clones for both histidine autotrophy and {beta}-galactosidase activity. Sequence analysis revealed that one of these clones, pMW6, contains two PDZ (PSD-95, Dlg, and ZO-1) domains (Fig. 1A). PDZ domains are found in a variety of proteins, some of which localize at cell-cell junctions and function as scaffolding proteins (21, 22), suggesting that vinexin may physiologically interact with this protein. Therefore, we focused on this clone in this study. BLAST search analysis of the GenBankTM data base suggested that sequences of pMW6 were identical to those of a part of the KIAA0583 gene (Fig. 1A). p-dlg was also part of KIAA0583 gene product (23) although there were no overlapping regions of p-dlg with pMW6 cDNA. Because KIAA0583 was predicted not to be a full-length cDNA, we first performed 5'-rapid amplification of cDNA ends. We isolated several clones and found that the two longest clones contained a stop codon upstream of ATG in-frame, suggesting that this ATG is the first codon. We, therefore, combined the 5'-rapid amplification of cDNA ends product with KIAA0583 to construct the full-length cDNA (Fig. 1A). This protein, named lp-dlg (large type of p-dlg), has four PDZ domains, an SH3 domain, and a GUK domain, which are conserved structures among most MAGUK family proteins. In addition to these conserved domains, lp-dlg has a coiled-coil region, which can work as a protein interacting region, at the NH2 terminus.



View larger version (72K):
[in this window]
[in a new window]
 
FIG. 1.
Schematic diagram of the domain structure of lp-dlg and its predicted amino acid sequences. A, lp-dlg contains the NH2-terminal coiled-coil region, four PDZ domains, an SH3 domain, and a GUK domain. Each domain is shown by boxes. MW6 is a cDNA clone isolated by two-hybrid screening. The region used as a probe for Northern blotting in Fig. 2 is shown as a solid line. Amino acid residues are numbered from the first methionine of lp-dlg. B, predicted amino acid sequence of lp-dlg (GenBankTM/EMBL/DDBJ accession number AB091676 [GenBank] ) is shown. PDZ domains are underlined once. The SH3 domain is underlined twice. The GUK domain is boxed.

 



View larger version (54K):
[in this window]
[in a new window]
 
FIG. 2.
Northern blotting and Western blotting of lp-dlg. A, Northern blotting using lp-dlg. The cDNA fragment, isolated by 5'-rapid amplification of cDNA ends shown in Fig. 1A, was labeled with 32P and hybridized with poly(A)+ RNA resolved by electrophoresis and transferred to a nylon membrane. Autoradiography of the blot is shown with the mobilities and sizes of molecular weight markers. B, protein samples extracted from COS-7, LLC-PK1, HeLa, and Madin-Darby canine kidney cells were resolved by SDS-PAGE, followed by Western blot analysis using the affinity purified anti-lp-dlg antibody.

 
We performed Northern blot analysis to determine the tissue distribution of lp-dlg mRNA. A human multiple tissue Northern blot was hybridized with the cDNA of the NH2-terminal region of lp-dlg (Fig. 1A). A major band of 8.5-kb transcripts was detected (Fig. 2A). A faint band of 4.5 kb was detected in some tissues (Fig. 2A). The expression level of lp-dlg was the highest in the placenta and modest in the brain, heart, skeletal muscle, and kidney. Interestingly, the short form of the alternative splicing variant, p-dlg, was reported to be expressed at a high level in placenta but not in the brain or heart (23), suggesting that splicing is regulated in a tissue-specific manner.

To confirm the expression of lp-dlg in cultured cells, Western blot analysis was performed using anti-lp-dlg polyclonal antibody. Two major protein bands of 250 and 200 kDa were detected at high levels in LLC-PK1 cells and moderately in other cell lines (Fig. 2B). Both proteins were also detected by another anti-lp-dlg antibody purified from a different rabbit serum (data not shown), suggesting that they are isoforms. To determine which proteins are translated from lp-dlg mRNA, full-length cDNA of lp-dlg was transfected into COS-7 cells. Proteins of 250 kDa were detected in addition to endogenous proteins (data not shown), suggesting that the 250-kDa protein is translated from lp-dlg mRNA and that the 200-kDa protein is from another splicing variant of lp-dlg.

Interaction of Vinexin with lp-dlg—To determine the region of the lp-dlg binding site in vinexin, various deletion mutants of vinexin were fused with the GAL4 DNA-binding domain (Fig. 3A). The two-hybrid system using these deletion mutants as bait plasmids and pMW6 as a prey plasmid were performed. Transformants containing vinexin {beta}, 2nd+3rdSH3, and 3rdSH3 showed histidine autotrophy, suggesting that vinexin {beta} binds to lp-dlg through its third SH3 domain (Fig. 3B). To further confirm the interaction of vinexin {beta} with lp-dlg in vitro, various SH3 domains of vinexin {beta} were expressed and purified as GST fusion proteins. These GST fusion proteins were immobilized on a glutathione-Sepharose 4B and incubated with cell lysates from COS-7 cells expressing FLAG-MW6. The bound proteins were analyzed by immunoblotting using an anti-FLAG antibody. Consistent with the results of the yeast two-hybrid system, GST-vinexin {beta} and GST-3rdSH3 were able to interact with FLAG-MW6 (Fig. 4A). In contrast, neither GST-1stSH3 nor GST-2ndSH3 bound to FLAG-MW6 (Fig. 4B), suggesting that the interaction of the third SH3 domain of vinexin and lp-dlg is specific. Furthermore, the 3rdWF mutant (tryptophan residue at position 306 to phenylalanine) and the 3rdYV mutant (tyrosine residue at position 324 to valine), which lost the binding ability to the target protein Sos (14), could not interact with FLAG-MW6 (Fig. 4B). Together these results suggest that lp-dlg binds to vinexin specifically and that the third SH3 domain of vinexin was responsible for this interaction.



View larger version (55K):
[in this window]
[in a new window]
 
FIG. 3.
Vinexin {beta}-lp-dlg interaction assayed by histidine autotrophy in the yeast two-hybrid system. A, a schematic diagram of deletion constructs. B, the yeast transformants bearing the deletion mutants of vinexin {beta} as baits and pMW6 as prey were streaked on the synthetic medium plate with (left panel) or without histidine (right panel). Growth in the absence of histidine indicates the interaction in driving expression of HIS3. The results are representative of three independent experiments.

 


View larger version (20K):
[in this window]
[in a new window]
 
FIG. 4.
In vitro association of lp-dlg with the third SH3 domain of vinexin {beta} A and B, cell lysates from COS-7 cells transfected with FLAG-tagged MW6 were incubated with GST-fused vinexin deletion mutants shown in Fig. 3 and precipitated by glutathione-Sepharose beads. The precipitates were washed and resolved by SDS-PAGE and then immunoblotted with anti-FLAG M2 antibody. Point mutants of the third SH3 domain (3rdSH3WF and 3rdSH3YV) are described under "Experimental Procedures." The results are representative of three independent experiments.

 

To map the vinexin binding site in lp-dlg, various deletion mutants of lp-dlg (Fig. 5A) tagged with the FLAG epitope were transfected into COS-7 cells. These mutants were expressed comparably in COS-7 cells (Fig. 5B). Cell lysates were then incubated with GST-vinexin {beta}. Immunoblotting using anti-FLAG antibody against the bound proteins showed that vinexin {beta} interacted with FLAG-MW6, 644–909, 842–909, and 842–879 strongly but not 880–909 (Fig. 5B). Similar results were also obtained using GST-3rdSH3 in place of GST-vinexin {beta} (data not shown). These results suggest that the third SH3 domain of vinexin {beta} binds to the region of 842–879 of lp-dlg, which contains proline-rich putative SH3 binding sequences.



View larger version (42K):
[in this window]
[in a new window]
 
FIG. 5.
Deletion analysis of lp-dlg on its in vitro association with vinexin {beta} A, a schematic diagram of deletion constructs. B, cell lysates from COS-7 cells transfected with FLAG-tagged various deletion mutants of lp-dlg were incubated with GST-vinexin {beta} and glutathione-Sepharose beads. The precipitates were washed and resolved by SDS-PAGE and then immunoblotted with anti-FLAG M2 antibody. FLAG-tagged deletion mutants were expressed at comparable levels in COS-7 cells. The results are representative of three independent experiments.

 

To confirm the in vivo association of vinexin {beta} with lp-dlg, co-immunoprecipitation experiments were performed. GFP-tagged vinexin {beta} was transfected with or without FLAG-MW6 into COS-7 cells. Equal amounts of total protein lysates were immunoprecipitated using anti-FLAG antibody. As shown in Fig. 6A, GFP-vinexin {beta} was co-precipitated with FLAG-MW6. To verify the interaction of vinexin with full-length lp-dlg, FLAG-tagged vinexin {alpha} and {beta} were expressed in LLC-PK1 cells. Total cell lysates were immunoprecipitated using anti-FLAG antibody, and co-precipitated endogenous lp-dlg was examined by immunoblotting using anti-lp-dlg antibody. Precipitated lp-dlg was detected in cells expressing both FLAG-tagged vinexin {alpha} and {beta}, but not in LLC-PK1 (Fig. 6B). Together these observations suggest that vinexin {beta} interacts with lp-dlg both in vitro and in vivo.



View larger version (31K):
[in this window]
[in a new window]
 
FIG. 6.
In vivo association of lp-dlg with vinexin {beta} A, COS-7 cells were transfected with vector alone or FLAG-tagged MW6 with GFP-tagged vinexin {beta}. Cell lysates were immunoprecipitated (IP) with anti-FLAG antibody. Immunocomplexes were subjected to immunoblotting using anti-GFP antibody to detect the co-precipitated GFP-tagged vinexin {beta}. Cell lysates were immunoblotted using anti-GFP antibody to confirm the equal expression of GFP-vinexin {beta}. The results are representative of three independent experiments. B, expression of FLAG-tagged vinexin {alpha} and {beta} were induced for 2 days as described under "Experimental Procedures." Cell lysates were immunoprecipitated with anti-FLAG antibody. Immunocomplexes were subjected to immunoblotting using anti-lp-dlg antibody to detect the co-precipitated endogenous lp-dlg. Cell lysates were immunoblotted using anti-lp-dlg (upper panel) or anti-FLAG antibody (lower panel) to confirm the expression of lp-dlg and FLAG-vinexins, respectively. Arrowhead indicates the alternative splicing variant of lp-dlg (see Fig. 2B).

 

Subcellular Localization of lp-dlg—To determine whether lp-dlg and vinexin are colocalized at sites of cell-cell contact, GFP-tagged vinexin {beta} was transfected into LLC-PK1 cells where lp-dlg was expressed at a high level. The subcellular localization of vinexin {beta} was observed by GFP fluorescence, and the same cells were also stained with anti-lp-dlg polyclonal antibody and Alexa 568-labeled secondary antibody. GFP-tagged vinexin {beta} showed the localization at both sites of cell-cell and cell-extracellular matrix junctions, in addition to a diffuse pattern (Fig. 7A). Endogenous lp-dlg was also concentrated at sites of cell-cell contact and colocalized with vinexin {beta} (Fig. 7A). Interestingly, lp-dlg was not concentrated at sites of cell-extracellular matrix junction (Fig. 7A, inset). Furthermore, lp-dlg was partially colocalized with {beta}-catenin, a major component of adherens junctions (Fig. 7B). We also examined the localization of lp-dlg protein in frozen tissue sections of mouse placenta, where lp-dlg mRNA was expressed at high levels (Fig. 2A), and found that lp-dlg and {beta}-catenin were also colocalized in tissues (data not shown).



View larger version (43K):
[in this window]
[in a new window]
 
FIG. 7.
Subcellular localization of lp-dlg. A, LLC-PK1 cells transfected with GFP-vinexin {beta} were fixed with methanol. Cells were then observed for GFP fluorescence (green) and indirect immunofluorescence against anti-lp-dlg antibody (red). Merged image of the staining is also shown (right panel). Arrowheads indicate co-localization of vinexin {beta} and lp-dlg. Inset, images of sections at basal level of transfected LLC-PK1 cells. Arrows show the localization of vinexin {beta} at sites of cell-extracellular matrix junction, where lp-dlg was not localized. B, LLC-PK1 cells were fixed with acetone and then doubly stained with anti-{beta}-catenin (green) and anti-lp-dlg (red) antibodies. Merged image of the staining is also shown (right panel). Arrowheads indicate co-localization of {beta}-catenin and lp-dlg. The results are representative of three independent experiments. Bar, 10 µm.

 

Interaction of lp-dlg with {beta}-Catenin—Co-localization of lp-dlg and {beta}-catenin both in cultured cells and in tissues raises the possibility of the interaction between these two molecules. To examine this possibility, FLAG-tagged lp-dlg mutants were transiently expressed in COS-7 cells by transfection with GFP-tagged {beta}-catenin. Equal amounts of total protein lysates were immunoprecipitated using anti-FLAG antibody. As shown in Fig. 8A, GFP-{beta}-catenin was co-precipitated with FLAG-MW6 but not with vector alone, suggesting that lp-dlg can associate with {beta}-catenin. FLAG-MW6 also contained the binding site (842–879) for vinexin {beta} as described above (see Fig. 5B). To determine whether vinexin {beta} and {beta}-catenin share the binding site in lp-dlg, a co-immunoprecipitation experiment using another deletion mutant (FLAG-(644–909)) was performed (Fig. 8A). FLAG-(644–909) contains the binding site for vinexin {beta} but not the first and second PDZ domains. GFP-{beta}-catenin was not co-immunoprecipitated with FLAG-(644–909). These results suggest that the binding site of lp-dlg for {beta}-catenin is different from that for vinexin {beta}.



View larger version (43K):
[in this window]
[in a new window]
 
FIG. 8.
In vivo association of lp-dlg with {beta}-catenin. A, FLAG-MW6, FLAG-644–909, or vector alone were expressed in COS-7 cells by transfection with GFP-{beta}-catenin. Cell lysates were immunoprecipitated (IP) with anti-FLAG antibody. Immunocomplexes were subjected to immunoblotting using anti-GFP antibody to detect the co-precipitated GFP-{beta}-catenin. Cell lysates were immunoblotted using anti-GFP antibody to confirm the equal expression of {beta}-catenin. B, lysates extracted from LLC-PK1 cells were immunoprecipitated with anti-lp-dlg antibody (5 µg) or preimmune serum (1 µl). Immunocomplexes were subjected to immunoblotting with anti-{beta}-catenin antibody. C, FLAG-MW6, HA-{beta}-catenin, or both proteins were transiently expressed in COS-7 cells by transfection with GFP-vinexin {beta}. Cell lysates were immunoprecipitated with anti-HA antibody. Immunocomplexes were subjected to immunoblotting using anti-GFP antibody or anti-FLAG antibody to detect the co-precipitated GFP-vinexin {beta} and FLAG-MW6, respectively. Note that GFP-vinexin {beta} was co-immunoprecipitated with HA-{beta}-catenin when FLAG-MW6 was expressed. Cell lysates were also immunoblotted using anti-GFP, anti-FLAG, or anti-HA antibodies to confirm the expression of each protein. The results are representative of three independent experiments.

 

To confirm the interaction of lp-dlg with {beta}-catenin, endogenous lp-dlg was immunoprecipitated using anti-lp-dlg polyclonal antibody from lysates of LLC-PK1 cells, in which lp-dlg was expressed at high levels. Precipitates were evaluated by immunoblotting with anti-{beta}-catenin antibody. Fig. 8B showed that endogenous {beta}-catenin was co-immunoprecipitated with endogenous lp-dlg. {beta}-Catenin was not detected in the precipitate using preimmune serum. E-cadherin and {alpha}-catenin showed very weak association with lp-dlg compared with that of {beta}-catenin (data not shown). These results suggest that lp-dlg associates with {beta}-catenin as well as vinexin at sites of cell-cell contact.

To determine whether lp-dlg forms a ternary complex with vinexin {beta} and {beta}-catenin, GFP-vinexin {beta} and HA-{beta}-catenin were transiently expressed in COS-7 cells with or without FLAG-MW6, and then immunoprecipitated with anti-HA antibody. GFP-vinexin {beta} was barely co-precipitated with HA-{beta}-catenin without FLAG-MW6 (Fig. 8C). However, GFP-vinexin {beta} was co-precipitated significantly with HA-{beta}-catenin when FLAG-MW6, which includes the binding sites for both vinexin {beta} and {beta}-catenin, was coexpressed (Fig. 8C). This observation suggests that lp-dlg can form a ternary complex with vinexin {beta} and {beta}-catenin and function as a scaffolding protein.


    DISCUSSION
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Vinexin is a vinculin-binding protein localized at cell-cell and cell-extracellular matrix junctions. We previously showed that vinexin enhances cell spreading and cytoskeletal organization and regulates the anchorage dependence of extracellular signal-regulated kinase activation, but the roles of vinexin at cell-cell junctions is not known. In this study, we identified a novel MAGUK protein, lp-dlg, as a binding partner of vinexin. We showed that lp-dlg binds to vinexin both using the two-hybrid system and by in vitro binding assay. Immunoprecipitation assay showed that they can also make a complex in vivo. In addition, lp-dlg and vinexin were colocalized at sites of cell-cell contact. lp-dlg was also colocalized with and bound to {beta}-catenin, a major adherens junction protein. These observations suggest that lp-dlg is a novel binding partner of vinexin at sites of cell-cell contact.

{beta}-Catenin connects the cytoplasmic domain of cadherin to {alpha}-catenin, which then binds to the actin cytoskeleton directly or indirectly thorough vinculin. In this study, we showed that both the endogenous and the deletion mutants of lp-dlg can bind to {beta}-catenin. The region (472–644) containing the first and second PDZ domains of lp-dlg were required for this association. {beta}-Catenin has been shown to have a PDZ-target like sequence (-DTDL) at its COOH-terminal end and to bind to proteins containing PDZ domains (24, 25). Thus, the first or second PDZ domain of lp-dlg may mediate the interaction of lp-dlg with {beta}-catenin. We also showed that lp-dlg can form a ternary complex with {beta}-catenin and vinexin {beta}. The function of this complex is unclear so far. However, it is possible that the {beta}-catenin·lp-dlg·vinexin complex can link cadherin to actin cytoskeleton through vinexin binding to vinculin and contribute to the formation of cell-cell contacts. Alternatively, {beta}-catenin·lp-dlg complex might compete with the vinexin binding to Sos, a guanine nucleotide exchange factor for Ras and Rac, and modulate the signaling, because both Sos and lp-dlg bind to the third SH3 domain of vinexin {beta} (14). Further studies are necessary to examine these possibilities.

lp-dlg contains an NH2-terminal coiled-coil region, four PDZ domains, an SH3 domain, and a GUK domain, and belongs to the MAGUK protein family. This domain structure is slightly different from typical MAGUK proteins, which have one or three PDZ domains and no coiled-coil regions. In addition, none of the four PDZ domains of lp-dlg have the GLGF motif, which is conserved in most PDZ domains and is necessary for binding to S/T-X-{varphi} ({varphi} is a hydrophobic residue). A recently proposed classification (26) also classified the four PDZ domains of lp-dlg into different groups from the PDZ domains of typical MAGUK proteins. Thus, lp-dlg may have different target proteins and different functions from other MAGUK proteins.

We showed that the third SH3 domain of vinexin {beta} bound to the region of 842–879 of lp-dlg. This binding was specific, because neither the first nor the second SH3 domain of vinexin {beta} bound to lp-dlg. In addition, the result that point mutations in the third SH3 domains disrupted the binding ability to lp-dlg suggests the specific interaction, although other proteins containing SH3 domain may also bind to lp-dlg. The region of 842–879 of lp-dlg included the proline-rich sequences, RagPlt-PPkPPRR. Two sequence motifs, RXXPXXP and PXXPXR, were reported to be a consensus for binding to SH3 domains (27). Interestingly, the proline-rich sequences in 842–879 of lp-dlg contain both consensus motifs, suggesting that they mediate the interaction with the third SH3 domain of vinexin {beta}.

During preparation of the present manuscript, another splicing variant of lp-dlg, DLG5, was reported (28). DLG5 was isolated from the heart as one of the genes located on chromosome 10q22, where familial atrial fibrillation was mapped, and excluded as a possible cause of familial atrial fibrillation (28). DLG5 contains an additional 45 amino acids at the NH2-terminal compared with lp-dlg. Both DLG5 and lp-dlg cDNA contain stop codons upstream of their first ATG in-frame, suggesting that both products include whole coding regions of each product. lp-dlg was isolated from placenta, where lp-dlg/DLG5 expression is high, and DLG5 from the heart, where lp-dlg/DLG5 expression is lower (Fig. 2). Thus, lp-dlg and DLG5 may represent the splicing variant expressed in the placenta and heart, respectively.


    FOOTNOTES
 
* This work was supported in part by the Yoshitomi Medical Research Foundation, The Sagawa Foundation for Promotion of Cancer Research, The Asahi Glass Foundation, and a grant-in-aid for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology of Japan. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

{ddagger} To whom correspondence should be addressed. Fax: 81-75-753-6104; E-mail: nkioka{at}kais.kyoto-u.ac.jp.

1 The abbreviations used are: SH3, Src homology 3; ERK, extracellular signal-regulated kinase; MAGUK, membrane-associated guanylate kinase; GST, glutathione S-transferase; HA, hemagglutinin; GFP, green fluorescent protein. Back


    ACKNOWLEDGMENTS
 
We thank Dr. T. Nagase, Dr. M. Ozawa, and Dr. M. Hagiwara for the generous gifts of KIAA0583 cDNA, {beta}-catenin cDNA, and pLRT-X, respectively.



    REFERENCES
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Takeichi, M. (1995) Curr. Opin. Cell Biol. 7, 619–627[CrossRef][Medline] [Order article via Infotrieve]
  2. Gumbiner, B. M. (1996) Cell 84, 345–357[Medline] [Order article via Infotrieve]
  3. Nagafuchi, A. (2001) Curr. Opin. Cell Biol. 13, 600–603[CrossRef][Medline] [Order article via Infotrieve]
  4. Takahashi, K., Nakanishi, H., Miyahara, M., Mandai, K., Satoh, K., Satoh, A., Nishioka, H., Aoki, J., Nomoto, A., Mizoguchi, A., and Takai, Y. (1999) J. Cell Biol. 145, 539–549[Abstract/Free Full Text]
  5. Aberle, H., Schwartz, H., and Kemler, R. (1996) J. Cell. Biochem. 61, 514–523[CrossRef][Medline] [Order article via Infotrieve]
  6. Yap, A. S., Brieher, W. M., and Gumbiner, B. M. (1997) Annu. Rev. Cell Dev. Biol. 13, 119–146[CrossRef][Medline] [Order article via Infotrieve]
  7. Mandai, K., Nakanishi, H., Satoh, A., Obaishi, H., Wada, M., Nishioka, H., Itoh, M., Mizoguchi, A., Aoki, T., Fujimoto, T., Matsuda, Y., Tsukita, S., and Takai, Y. (1997) J. Cell Biol. 139, 517–528[Abstract/Free Full Text]
  8. Mandai, K., Nakanishi, H., Satoh, A., Takahashi, K., Satoh, K., Nishioka, H., Mizoguchi, A., and Takai, Y. (1999) J. Cell Biol. 144, 1001–1017[Abstract/Free Full Text]
  9. Kioka, N., Sakata, S., Kawauchi, T., Amachi, T., Akiyama, S. K., Okazaki, K., Yaen, C., Yamada, K. M., and Aota, S. (1999) J. Cell Biol. 144, 59–69[Abstract/Free Full Text]
  10. Wang, B., Golemis, E. A., and Kruh, G. D. (1997) J. Biol. Chem. 272, 17542–17550[Abstract/Free Full Text]
  11. Ribon, V., Herrera, R., Kay, B. K., and Saltiel, A. R. (1998) J. Biol. Chem. 273, 4073–4080[Abstract/Free Full Text]
  12. Kioka, N., Ueda, K., and Amachi, T. (2002) Cell Struct. Funct. 27, 1–7[CrossRef][Medline] [Order article via Infotrieve]
  13. Suwa, A., Mitsushima, M., Ito, T., Akamatsu, M., Ueda, K., Amachi, T., and Kioka, N. (2002) J. Biol. Chem. 277, 13053–13058[Abstract/Free Full Text]
  14. Akamatsu, M., Aota, S., Suwa, A., Ueda, K., Amachi, T., Yamada, K. M., Akiyama, S. K., and Kioka, N. (1999) J. Biol. Chem. 274, 35933–35937[Abstract/Free Full Text]
  15. Weiss, E. E., Kroemker, M., Rudiger, A. H., Jockusch, B. M., and Rudiger, M. (1998) J. Cell Biol. 141, 755–764[Abstract/Free Full Text]
  16. Watabe-Uchida, M., Uchida, N., Imamura, Y., Nagafuchi, A., Fujimoto, K., Uemura, T., Vermeulen, S., van Roy, F., Adamson, E. D., and Takeichi, M. (1998) J. Cell Biol. 142, 847–857[Abstract/Free Full Text]
  17. Rudiger, M. (1998) Bioessays 20, 733–740[CrossRef][Medline] [Order article via Infotrieve]
  18. Hazan, R. B., Kang, L., Roe, S., Borgen, P. I., and Rimm, D. L. (1997) J. Biol. Chem. 272, 32448–32453[Abstract/Free Full Text]
  19. Fukada, T., Kioka, N., Nishiu, J., Sakata, S., Sakai, H., Yamada, M., and Komano, T. (1998) FEBS Lett. 436, 228–232[CrossRef][Medline] [Order article via Infotrieve]
  20. Watsuji, T., Okamoto, Y., Emi, N., Katsuoka, Y., and Hagiwara, M. (1997) Biochem. Biophys. Res. Commun. 234, 769–773[CrossRef][Medline] [Order article via Infotrieve]
  21. Dimitratos, S. D., Woods, D. F., Stathakis, D. G., and Bryant, P. J. (1999) Bioessays 21, 912–921[CrossRef][Medline] [Order article via Infotrieve]
  22. Harris, B. Z., and Lim, W. A. (2001) J. Cell Sci. 114, 3219–3231[Medline] [Order article via Infotrieve]
  23. Nakamura, H., Sudo, T., Tsuiki, H., Miyake, H., Morisaki, T., Sasaki, J., Masuko, N., Kochi, M., Ushio, Y., and Saya, H. (1998) FEBS Lett. 433, 63–67[CrossRef][Medline] [Order article via Infotrieve]
  24. Perego, C., Vanoni, C., Massari, S., Longhi, R., and Pietrini, G. (2000) EMBO J. 19, 3978–3989[Abstract/Free Full Text]
  25. Dobrosotskaya, I. Y., and James, G. L. (2000) Biochem. Biophys. Res. Commun. 270, 903–909[CrossRef][Medline] [Order article via Infotrieve]
  26. Bezprozvanny, I., and Maximov, A. (2001) FEBS Lett. 509, 457–462[CrossRef][Medline] [Order article via Infotrieve]
  27. Sparks, A. B., Rider, J. E., Hoffman, N. G., Fowlkes, D. M., Quillam, L. A., and Kay, B. K. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 1540–1544[Abstract/Free Full Text]
  28. Shah, G., Brugada, R., Gonzalez, O., Czernuszewicz, G., Gibbs, R. A., Bachinski, L., and Roberts, R. (2002) BMC Genomics, http://www.biomedcentral.com/1471-2164/3/6